Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib-Reference-Cited by-同舟云学术

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib

Published:2022-08-15 Issue:16 Volume:61 Page:2503-2508
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Sekiguchi Yasunobu¹,Nishimura You²,Kanda Hiroaki²,Kawamura Machiko³,Kobayashi Kazuhiko³,Kobayashi Hirofumi¹

Affiliation:

1. Department of Hematology, Saitama Cancer Center, Japan

2. Department of Pathology, Saitama Cancer Center, Japan

3. Department of Clinical Laboratory Medicine, Saitama Cancer Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/61/16/61_8760-21/_pdf

Reference25 articles.

1. 1. Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol 9: 80, 2016.

2. 2. Liclican A, Serafini L, Xing W, et al. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition. Biochim Biophys Acta Gen Subj 1864: 129531, 2020.

3. 3. Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol 26: e233-e240, 2019.

4. 4. Wu J, Zhang M, Liu D. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget 8: 7201-7207, 2017.

5. 5. Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia. Cancer Sci 111: 3327-3337, 2020.